These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 1685015)
21. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. Prelević GM; Würzburger MI; Perić LA J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696 [TBL] [Abstract][Full Text] [Related]
22. Evidence of altered dopaminergic modulation of Prl, LH and TSH secretion in patients with normoprolactinaemic amenorrhoea. Hagen C; Petersen K; Djursing H; Andersen AN Acta Endocrinol (Copenh); 1984 May; 106(1):8-14. PubMed ID: 6428118 [TBL] [Abstract][Full Text] [Related]
23. Effect of pyridoxine on human hypophyseal trophic hormone release: a possible stimulation of hypothalamic dopaminergic pathway. Delitala G; Masala A; Alagna S; Devilla L J Clin Endocrinol Metab; 1976 Mar; 42(3):603-6. PubMed ID: 1254699 [TBL] [Abstract][Full Text] [Related]
24. The acute effects of a dopamine antagonist (domperidone) on luteinising hormone, follicule stimulating hormone, prolactin and thyrotrophin secretion in polycystic ovarian syndrome: differential effect of ovulation. Murdoch AP; Dunlop W; Kendall-Taylor P; Watson MJ Clin Endocrinol (Oxf); 1984 Dec; 21(6):611-9. PubMed ID: 6439439 [TBL] [Abstract][Full Text] [Related]
26. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Paoletti AM; Cagnacci A; Soldani R; Orrù M; Ajossa S; Pittorra G; Mulas P; Melis GB Fertil Steril; 1995 Dec; 64(6):1094-8. PubMed ID: 7589658 [TBL] [Abstract][Full Text] [Related]
27. Enhanced prolactin secretion in patients with primary hypothyroidism during thyroid replacement. Sato S; Hanew K; Sasaki A; Shimizu Y; Murakami O; Fukazawa H; Sakurada T; Saito S; Yoshinaga K Tohoku J Exp Med; 1984 Dec; 144(4):425-31. PubMed ID: 6528338 [TBL] [Abstract][Full Text] [Related]
28. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. Barnes RB; Lobo RA J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677 [TBL] [Abstract][Full Text] [Related]
29. Can women with gonadotropin levels diagnostic of polycystic ovarian syndrome benefit from therapy with dopamine agonists? Harrison RF; Synnott M; O'Moore R; O'Moore M Ann N Y Acad Sci; 1993 May; 687():272-9. PubMed ID: 8100697 [TBL] [Abstract][Full Text] [Related]
30. Effects of dopamine and metoclopramide in polycystic ovary syndrome. Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335 [TBL] [Abstract][Full Text] [Related]
31. Effect of sulpiride-induced hyperprolactinaemia on catecholamine turnover and LRH concentration in the medial basal hypothalamus of rats. Chatani F; Aono T; Koike K; Tasaka K; Kurachi K Acta Endocrinol (Copenh); 1983 Mar; 102(3):321-6. PubMed ID: 6402870 [TBL] [Abstract][Full Text] [Related]
32. Uterine perfusion and hormonal pattern in patients with polycystic ovary syndrome. Ajossa S; Guerriero S; Paoletti AM; Orrù M; Floris S; Mannias M; Melis GB J Assist Reprod Genet; 2001 Aug; 18(8):436-40. PubMed ID: 11599464 [TBL] [Abstract][Full Text] [Related]
33. Acute endocrine profile of sulpiride in the human. L'Hermite M; Denayer P; Golstein J; Virasoro E; Vanhaelst L; Copinschi G; Robyn C Clin Endocrinol (Oxf); 1978 Sep; 9(3):195-204. PubMed ID: 709890 [TBL] [Abstract][Full Text] [Related]
34. Enhanced hypothalamic dopaminergic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinaemia. Ho KY; Smythe GA; Lazarus L Acta Endocrinol (Copenh); 1985 Mar; 108(3):289-96. PubMed ID: 3984660 [TBL] [Abstract][Full Text] [Related]
35. Effect of an antidopaminergic drug on LH, FSH and PRL levels in post-menopausal women. Venturini PL; Alibrandi MP; Costantini S; Grondona A; Morano S; Penna L; Valenzano M; Ragni N Acta Eur Fertil; 1981 Sep; 12(3):293-4. PubMed ID: 6803504 [No Abstract] [Full Text] [Related]
36. Prolactin secretion in polycystic ovary syndrome: circadian rhythmicity and dynamic aspects. Ferrari E; Bossolo PA; Foppa S; Dalzano M; Comis S; Morelli MP; Peveri V; Mengozzi A Gynecol Endocrinol; 1988 Jun; 2(2):101-11. PubMed ID: 3188970 [TBL] [Abstract][Full Text] [Related]
38. [Activity of clobazam on plasma prolactin and gonadotropins after administration of sulpiride in the male rat]. Valli M; Courtiere A; Tamalet C; Jadot G Ann Endocrinol (Paris); 1984; 45(6):409-11. PubMed ID: 6152598 [TBL] [Abstract][Full Text] [Related]
39. Identification of polycystic ovary syndrome from blood serum using hormone levels via Raman spectroscopy and multivariate analysis. Guleken Z; Bulut H; Bulut B; Paja W; Orzechowska B; Parlinska-Wojtan M; Depciuch J Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 273():121029. PubMed ID: 35217265 [TBL] [Abstract][Full Text] [Related]
40. To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study. Mahboobifard F; Rahmati M; Amiri M; Azizi F; Ramezani Tehrani F Adv Med Sci; 2022 Mar; 67(1):79-86. PubMed ID: 34998115 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]